Innoviva Net Income 2010-2024 | INVA

Innoviva net income from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Innoviva Annual Net Income
(Millions of US $)
2023 $180
2022 $214
2021 $266
2020 $224
2019 $157
2018 $395
2017 $134
2016 $60
2015 $-19
2014 $-168
2013 $-171
2012 $-19
2011 $-115
2010 $-84
2009 $-85
Innoviva Quarterly Net Income
(Millions of US $)
2024-06-30 $-35
2024-03-31 $37
2023-12-31 $62
2023-09-30 $82
2023-06-30 $1
2023-03-31 $35
2022-12-31 $-68
2022-09-30 $266
2022-06-30 $1
2022-03-31 $16
2021-12-31 $10
2021-09-30 $72
2021-06-30 $89
2021-03-31 $94
2020-12-31 $54
2020-09-30 $28
2020-06-30 $77
2020-03-31 $65
2019-12-31 $46
2019-09-30 $40
2019-06-30 $38
2019-03-31 $34
2018-12-31 $264
2018-09-30 $47
2018-06-30 $55
2018-03-31 $30
2017-12-31 $58
2017-09-30 $24
2017-06-30 $35
2017-03-31 $17
2016-12-31 $25
2016-09-30 $15
2016-06-30 $15
2016-03-31 $4
2015-12-31 $4
2015-09-30 $-5
2015-06-30 $-8
2015-03-31 $-11
2014-12-31 $-16
2014-09-30 $-21
2014-06-30 $-64
2014-03-31 $-68
2013-12-31 $-50
2013-09-30 $-47
2013-06-30 $-36
2013-03-31 $-37
2012-12-31 $-31
2012-09-30 $-35
2012-06-30 $-37
2012-03-31 $85
2011-12-31 $-37
2011-09-30 $-31
2011-06-30 $-25
2011-03-31 $-23
2010-12-31 $-19
2010-09-30 $-21
2010-06-30 $-21
2010-03-31 $-23
2009-12-31 $-22
2009-09-30 $-22
2009-06-30 $-22
2009-03-31 $-19
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.211B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $765.281B 79.27
Novo Nordisk (NVO) Denmark $492.372B 37.58
Johnson & Johnson (JNJ) United States $380.982B 15.45
AbbVie (ABBV) United States $354.099B 18.65
Merck (MRK) United States $258.017B 17.12
Novartis AG (NVS) Switzerland $225.903B 15.02
AstraZeneca (AZN) United Kingdom $221.475B 19.73
Pfizer (PFE) United States $157.307B 10.76
Sanofi (SNY) $134.378B 12.17